Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis

Journal of Hepatology

Volumn 30, Issue 3, 1999, Pages 479-484

  Stanley, Adrian J ^a   Therapondos, George ^a   Helmy, Ahmed ^a   Hayes, Peter C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Carvedilol; Cirrhosis; Hemodynamics; Portal hypertension; Renal function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; URINE VOLUME; VASCULAR RESISTANCE;

EID: 0033040460     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80108-1     Document Type: Article

References (35)

1. Lebrec D, Poynard T, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med. 305:1981;1371-1374.
2. Pascal JP, Cales P, Multicenter Study Group . Propranolol in the prevention of first upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 317:1987;856-861.
3. Lebrec D, Poynard T, Capron JP, Hillon P, Geoffroy P, Roulot D, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomised trial. J Hepatol. 7:1988;118-125.
4. Hayes PC, Davis JM, Lewis JA, Bouchier IAD. Meta-analysis of the value of propranolol in prevention of variceal haemorrhage. Lancet. 1:1990;153-156.
5. Conn HO, Grace N, Bosch J, Groszmann RJ, Rodes J, Wright SC, et al. members of the Boston-New Haven-Barcelona portal hypertension study group . Propranolol in the prevention of the first variceal haemorrhage from oesophageal varices: results of a randomized double-blind cooperative clinical trial. Hepatology. 13:1991;902-912.
6. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. the Franco-Italian Multicenter study group . B-adrenergicantagonists in the prevention of first gastrointestinal bleeding in patients with cirrhosis and oesophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med. 324:1991;1532-1538.
7. Pagliaro L, D'Amico G, Sorensen TIA, Lebrec D, Burroughs AK, Marabito A, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomised trials of non-surgical treatment. Ann Intern Med. 117:1992;59-70.
8. Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 104:1993;1460-1465.
9. Bertoni G, Sassatelli R, Fornaciari G, Briglia R, Tansini P, Grisendi A, et al. Oral isosorbide-5-mononitrate reduces the rebleeding rate during the course of injection sclerotherapy for esophageal varices. Scand J Gastroenterol. 29:1994;363-370.
10. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 22:1995;332-354.
11. Lebrec D. Pharmacotherapeutic agents in the treatment of portal hypertension. J Gastroenterol Hepatol. 12:1997;159-166.
12. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, et al. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology. 4:1984;1200-1205.
13. Garcia-Tsao G, Grace ND, Groszman RJ, Conn HO, Bormann MM, Patrick MJC, et al. Short-term effects of propranolol on portal pressure. Hepatology. 6:1986;101-106.
14. Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology. 11:1990;230-238.
15. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared to propranolol plus isosorbide-5-mononitrate for portal hypertension: a randomised controlled study. Ann Intern Med. 114:1991;869-873.
16. Vorbioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology. 18:1993;477-484.
17. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonata G, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology. 26:1997;34-39.
18. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Toboli P, et al. GTIP. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet. 348:1996;1677-1681.
19. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 334:1996;1624-1629.
20. Ljubicic N, Bilic A, Plavsic V. Effect of propranolol on urinary prostaglandin E2 excretion and renal interlobar arterial blood flow after furosemide administration in patients with hepatic cirrhosis. Eur J Clin Pharmacol. 43:1992;555-558.
21. Salmeron JM, Ruiz del Arbol L, Gines A, Garcia-Pagan JC, Gines P, Feu F, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology. 17:1993;800-806.
22. Bolognesi M, Sacerdoti D, Merkel C, Gatta A. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. J Ultrasound Med. 13:1994;945-952.
23. Sponer G, Strein K, Bartsch W, Muller-Beckmann B. Vasodilatory action of carvedilol. J Cardiovasc Pharm. 19:(suppl 1):1992;S5-S11.
24. Zweiten PA. Pharmacodynamic profile of carvedilol. Cardiology. 2:(suppl 3):1993;19-23.
25. Forrest EH, Bouchier IAD, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol. 25:1996;909-915.
26. Sekiyama T, Komeichi H, Nagano T, Ohsuga M, Terada H, Katsuta Y, et al. Effects of the alpha/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Arzneimittelforschung. 47:1997;353-355.
27. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
28. Cales P, Braillon A, Jiron MI, Lebrec D. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. J Hepatol. 1:1985;37-46.
29. Neugebauer G, Gabor M, Reiff K. Pharmacokinetics and bioavailability of carvedilol in patients with cirrhosis. Drugs. 36:(suppl 6):1988;148-154.
30. Banares R, Garcia-Pagan JC, Piqueras B, Casado M, Moitinho E, Diego A, et al. Carvedilol, a new non-selective Beta-blocker with intrinsic anti-alpha adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. [abstract] Hepatology. 26:1997;133A.
31. Grace ND. Management of portal hypertension. Gastroenterologist. 1:1997;39-58.
32. Rector WG Jr, Reynolds TB. Propranolol in the treatment on cirrhotic ascites. Arch Intern Med. 144:1984;1761-1763.
33. Morrillos RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology. 20:1994;1502-1508.
34. Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology. 22:1995;808-813.
35. Sugano S, Kawafune T, Suzuki T, Kubota M, Okajimi T, Sumio Y, et al. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis. Am J Gastroenterol. 90:1995;788-793.